Excess Mortality by Multimorbidity, Socioeconomic, and Healthcare Factors, amongst Patients Diagnosed with Diffuse Large B-Cell or Follicular Lymphoma in England.

dc.contributor.authorSmith, Matthew James
dc.contributor.authorBelot, Aurélien
dc.contributor.authorQuartagno, Matteo
dc.contributor.authorLuque Fernandez, Miguel Angel
dc.contributor.authorBonaventure, Audrey
dc.contributor.authorGachau, Susan
dc.contributor.authorBenitez Majano, Sara
dc.contributor.authorRachet, Bernard
dc.contributor.authorNjagi, Edmund Njeru
dc.date.accessioned2025-01-07T12:31:14Z
dc.date.available2025-01-07T12:31:14Z
dc.date.issued2021-11-19
dc.description.abstract(1) Background: Socioeconomic inequalities of survival in patients with lymphoma persist, which may be explained by patients' comorbidities. We aimed to assess the association between comorbidities and the survival of patients diagnosed with diffuse large B-cell (DLBCL) or follicular lymphoma (FL) in England accounting for other socio-demographic characteristics. (2) Methods: Population-based cancer registry data were linked to Hospital Episode Statistics. We used a flexible multilevel excess hazard model to estimate excess mortality and net survival by patient's comorbidity status, adjusted for sociodemographic, economic, and healthcare factors, and accounting for the patient's area of residence. We used the latent normal joint modelling multiple imputation approach for missing data. (3) Results: Overall, 15,516 and 29,898 patients were diagnosed with FL and DLBCL in England between 2005 and 2013, respectively. Amongst DLBCL and FL patients, respectively, those in the most deprived areas showed 1.22 (95% confidence interval (CI): 1.18-1.27) and 1.45 (95% CI: 1.30-1.62) times higher excess mortality hazard compared to those in the least deprived areas, adjusted for comorbidity status, age at diagnosis, sex, ethnicity, and route to diagnosis. (4) Conclusions: Deprivation is consistently associated with poorer survival among patients diagnosed with DLBCL or FL, after adjusting for co/multimorbidities. Comorbidities and multimorbidities need to be considered when planning public health interventions targeting haematological malignancies in England.
dc.identifier.doi10.3390/cancers13225805
dc.identifier.issn2072-6694
dc.identifier.pmcPMC8616469
dc.identifier.pmid34830964
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8616469/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2072-6694/13/22/5805/pdf?version=1637326695
dc.identifier.urihttps://hdl.handle.net/10668/24679
dc.issue.number22
dc.journal.titleCancers
dc.journal.titleabbreviationCancers (Basel)
dc.language.isoen
dc.organizationEscuela Andaluza de Salud Pública
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectcancer epidemiology
dc.subjectcomorbidity
dc.subjectdiffuse large B-cell lymphoma
dc.subjectfollicular lymphoma
dc.subjectmultimorbidity
dc.subjectsocioeconomic status
dc.subjectsurvival analysis
dc.titleExcess Mortality by Multimorbidity, Socioeconomic, and Healthcare Factors, amongst Patients Diagnosed with Diffuse Large B-Cell or Follicular Lymphoma in England.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number13

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8616469.pdf
Size:
5.97 MB
Format:
Adobe Portable Document Format